Stand out for this role — generate a tailored resume and cover letter in about a minute.
ImmunoVec seeks a Director of Business Development to drive strategic partnerships and translate its programmable DNA technology into collaboration opportunities with pharma, biotech, and VC communities.
You will lead relationship-building, negotiate term sheets and agreements, and collaborate with executive and legal teams to position ImmunoVec for future financing and clinical success.
Location: Hybrid (Preference for Boston, San Diego, or Los Angeles). Requires travel to the Los Angeles home office at least twice per month
Reports To: Chief Executive Officer and Chief Financial Officer
Compensation: $150,000 per year for exceptional candidates, plus equity. Additional bonuses and equity tied to performance.
ImmunoVec is a pioneering biotechnology company developing in vivo cell therapies for autoimmune diseases, cancer, and genetic disorders. Launched from stealth in October 2025 with $40.7 million in funding from ARPA-H’s EMBODY program and additional private capital,
ImmunoVec is pioneering the next generation of programmable cell therapies.
Our proprietary platform combines cell type-specific DNA constructs with targeted non-viral delivery vehicles to enable durable and precise in vivo cell engineering.
We are seeking a relentless and charismatic Director of Business Development to build the partnerships and relationships that will scale our impact.
We are looking for a highly energized relationship builder and strategic Business Development leader to serve as a key external face for ImmunoVec. As Director of Business Development, you will translate ImmunoVec’s differentiated platform science into compelling partnership opportunities, sharing the company’s story with top-tier pharmaceutical companies, biotech innovators, and the venture capital community. The role requires someone who can operate at both strategic and transactional levels, forging relationships, advancing partnership frameworks, and driving deal flow that positions the company for long-term commercial and clinical success.